HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study

Abstract

<i>HER2</i>-low expression does not affect the clinical efficacy of palbociclib and our present study did not support incorporating <i>HER2</i>-low into systemic therapy decisions for patients with HR+/<i>HER2</i>- metastatic breast cancer treated with <i>CDK4/6</i> inhibitor.